NVCT
Nuvectis Pharma Inc
NASDAQ: NVCT · HEALTHCARE · BIOTECHNOLOGY
$10.00
+2.99% today
Updated 2026-05-06
Market cap
$268.66M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.31
Dividend yield
—
52W range
$6 – $11
Volume
0.1M
WallStSmart proprietary scores
17
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C5.0
Quality
C+3.0
Profitability
D5.0
Valuation
C+—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →197 stocks currently score above 75
Price targets
Analyst target
$16.80
+68.00%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
2 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
Insufficient data
Risks
- Thin margins at 0.00%
- Negative free cash flow $-3.97M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $149000.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-18.79M | $-22.26M | $-19.00M | $-26.44M | $-7.31M |
| EPS | — | — | — | — | $-1.31 |
| Free cash flow | $-13.56M | $-15.95M | $-12.25M | $-16.01M | $-3.97M |
| Profit margin | -12,608.72% | — | — | — | — |
Peer comparison
Smart narrative
Nuvectis Pharma Inc trades at $10.00. Our Smart Value Score of 17/100 indicates the stock is weak.
Frequently asked questions
What is Nuvectis Pharma Inc's stock price?
Nuvectis Pharma Inc (NVCT) trades at $10.00.
Is Nuvectis Pharma Inc overvalued?
Smart Value Score 17/100 (Grade F, Strong Sell).
What is the price target of Nuvectis Pharma Inc (NVCT)?
The analyst target price is $16.80, representing +68.0% upside from the current price of $10.00.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-188.00%
Beta-0.12
50D MA$8.51
200D MA$7.39
Shares out0.03B
Float0.02B
Short ratio—
Avg volume0.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—